Understanding how XPD influences DNA damage responses
Role of XPD in DNA Damage Response Pathway Choice
This study is looking at how a protein called XPD helps cells choose between fixing their damaged DNA or shutting down completely, which is important for understanding how cancer treatments like chemotherapy affect cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10863985 on NIH RePORTER |
What this research studies
This research investigates the role of the XPD protein in deciding whether cells repair DNA damage or undergo programmed cell death (apoptosis). By examining the interactions between DNA repair mechanisms and apoptosis pathways, the study aims to uncover how cells respond to harmful DNA damage caused by various factors, including chemotherapy. The research employs advanced molecular biology techniques to analyze the signaling processes that guide these critical cellular decisions, which could have implications for cancer treatment and prevention.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that involve DNA damage and repair mechanisms, particularly those undergoing chemotherapy.
Not a fit: Patients with non-cancerous conditions or those whose DNA damage responses are not influenced by the XPD protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for enhancing cancer treatment by manipulating how cells respond to DNA damage.
How similar studies have performed: Previous research has shown promising results in understanding DNA damage responses, but the specific role of XPD in this context is still being explored, making this a novel investigation.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Rogers, Faye a — Yale University
- Study coordinator: Rogers, Faye a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.